The CEO of a plan that bungled production of 15 million Johnson & Johnson coronavirus vaccine doses receive a 51 percent increase in compensation in 2020, according to a report from The Washington Post.
Emergent Biosolutions CEO Robert Kramer received $5.6 million in 2020, according to a public filing reviewed by the Post on Friday.
The company executive received an $893,000 salary, $1.4 million from stock options, $2.1 million from stock award and a $1.2 million bonus, according to the Post.
According to the filing, the company increased Kramer’s pay after the company’s manufacturing business expanded and the CEO responded to the pandemic.
The company also reported a 41 percent increase in revenue in 2020. Kramer rose to CEO of the company in 2019, and has been with the company since 2012, according to the paper.
Emergent saw that increase in growth last year mainly due to a federal contract that gave the company $628 million to help fight the coronavirus pandemic, according to the newspaper.
The Post noted however that the bonuses came before the company’s Maryland plant contaminated 15 million Johnson & Johnson vaccine doses.
At the end of March, the issues surrounding vaccine production at the Emergent plant became public after the Johnson & Johnson vaccine was contaminated with ingredients from the AstraZeneca vaccine, according to the Post.
AstraZeneca materials have been completely moved from the facility and Johnson & Johnson is taking charge of the oversight for the plant.
The White House warned Friday that states will receive a substantially lower amount of the Johnson & Johnson vaccine over the coming weeks as a result of the mishap.
The New York Times earlier this week reported that there was a high risk for cross-contamination found in audits of the facility last year. The staff was also reported to be undertrained.
The Hill has reached out to Emergent Solutions for comment.